DK143275B - Analogifremgangsmaade til fremstilling af 1-(3-dimethylaminopropyl)-phthalanderivater eller syreadditionssalte deraf - Google Patents
Analogifremgangsmaade til fremstilling af 1-(3-dimethylaminopropyl)-phthalanderivater eller syreadditionssalte deraf Download PDFInfo
- Publication number
- DK143275B DK143275B DK13177AA DK13177A DK143275B DK 143275 B DK143275 B DK 143275B DK 13177A A DK13177A A DK 13177AA DK 13177 A DK13177 A DK 13177A DK 143275 B DK143275 B DK 143275B
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- dimethylaminopropyl
- ether
- acid addition
- Prior art date
Links
- -1 3-DIMETHYLAMINOPROPYL Chemical class 0.000 title claims description 27
- 239000002253 acid Substances 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 12
- 150000003839 salts Chemical class 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000004791 alkyl magnesium halides Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000000155 melt Substances 0.000 description 18
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 10
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 235000011054 acetic acid Nutrition 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000000966 norepinephrine reuptake Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000002295 serotoninergic effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YKOAIJCWPZQIQX-UHFFFAOYSA-N 1-[4-bromo-2-(hydroxymethyl)phenyl]-1-(4-chlorophenyl)-4-(dimethylamino)butan-1-ol Chemical compound C=1C=C(Br)C=C(CO)C=1C(O)(CCCN(C)C)C1=CC=C(Cl)C=C1 YKOAIJCWPZQIQX-UHFFFAOYSA-N 0.000 description 1
- NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- WOLPGGGWZDXCNM-UHFFFAOYSA-N 3-[5-bromo-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine Chemical compound O1CC2=CC(Br)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WOLPGGGWZDXCNM-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3h-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014405 Electrocution Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- VPWZLPOILJLUND-UHFFFAOYSA-N [4-bromo-2-(hydroxymethyl)phenyl]-(4-chlorophenyl)methanone Chemical compound OCC1=CC(Br)=CC=C1C(=O)C1=CC=C(Cl)C=C1 VPWZLPOILJLUND-UHFFFAOYSA-N 0.000 description 1
- GCJYYUGXODRJJT-UHFFFAOYSA-N [4-bromo-2-(hydroxymethyl)phenyl]-(4-fluorophenyl)methanol Chemical compound OCC1=CC(Br)=CC=C1C(O)C1=CC=C(F)C=C1 GCJYYUGXODRJJT-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- NGPAITITALWALP-UHFFFAOYSA-M magnesium;n,n-dimethylpropan-1-amine;chloride Chemical compound [Mg+2].[Cl-].CN(C)CC[CH2-] NGPAITITALWALP-UHFFFAOYSA-M 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
(19) DANMARK
f|| ('2) FREMUEGGELSESSKRIFT ου 143275 B
DIREKTORATET FOR PATENT- OG VAREMÆRKEVÆSENET
(21) Ansøgning nr. 131/77 (51) ,ntC|3 q q7 D 307/87 (22) Indleveringsdag 1^·· jan. 1977 (24) Løbedag 14. jan. 1977 (41) Aim. tilgængelig 15· jul. 1977 (44) Fremlagt 3· aug. 1981 (86) International ansøgning nr. -(86) International indleveringsdag -(85) Videreførelsesdag -(62) Stamansøgning nr. -
(30) Prioritet 14. jan. 1976, 1486/76, GB
(71) Ansøger KEFALAS A/S, Ottiliavej 7-9 , 2500 Valby, DK.
(72) Opfinder Klaus Peter Bøgesø, DK: Anders Stausbøll Toft, DK.
(74) Fuldmægtig - (54) Analogifremgangsmåde til fremstil®
Ung af 1 -(5-dimethylaminopropyl)-phthalanderivater eller syreaddl® tionssalte deraf.
m o V,
N
.i Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af hidtil ukendte phthalaner med den ^ almene formel: □ 2 143275 22 '^2^0 6'r^S2' 5'S^3' R2 1 2 hvori R og R hver repræsenterer halogen, en trifluormethyl-gruppe, en cyanogruppe eller R-C0-, hvori R er en alkylgruppe med fra 1-4 carbonatomer inklusive, eller syreadditionssalte af disse forbindelser med farmaceutisk akcepterbare syrer.
I mange år er endogene depressioner blevet anset for at være knyttet til nedsat aktivitet af centrale adrenerge processer, og den antidepressive virkning af imipraminlignende forbindelser antoges at være resultatet af en hæmning af noradrenalin-genoptagelsen. I overensstemmelse hermed koncentreredes anstrengelserne om at finde stoffer, som potenserede noradrenalin ved at forhindre genoptagelsen i cellevævet. Mellem phthalaner, beskrevet i beskrivelsen til dansk patent nr. 114,981, fandtes den mest aktive noradrenalinpotenserende forbindelse at have to methylgrupper i 3-stillingen, ingen substituenter i ringsystemets fenylkerne, en usubstitueret fenylring knyttet til position 1 og en monomethylaminopropylgruppe knyttet til position 1. Som det fremgår af artiklen af P.V.Petersen m.fl. i Acta pharmacol. et toxicol. 1966, Vol.24, p.121 og følgende, var det i realiteten kun forbindelser med to methylgrupper i position 3, som havde en rimelig potenserende effekt på noradrenalin.
På grundlag af nylige fremskridt i udforskningen af farmakologi og biokemi af antidepressiva og depressioner har Carlsson m.fl. i "Effect og antidepressant drugs on the 3 143275 depletion of intraneuronal brain 5-hydroxytryptainine stores caused by 4-methyl-0( -ethyl-meta-tyramine" :
Europ.J.Pharmacol. 1969, 5y 357-366, foreslået, at blokade af 5-hydroxytryptamin-genoptagelse er omfattet af den hævning af stemningslejet, som tricykliske antidepressiva medfører, hvorimod blokade af noradrenalin-genoptagelsen fremmer handlekraft hos deprimerede patienter. Også Lapin & Oxenkrug: "Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect": Lancet 1969, 1^, 132-136, foreslår, at hævningen af stemningslejet forårsaget af monoaminooxydasehæmmere og af elektrochock er knyttet til en intensivering af serotoninerge processer i hjernen.
Det har nu overraskende vist sig, at phthalaner med formlen I, såvel som deres syreadditionssalte med farmaceutisk akcepter-bare syrer, har kraftigt potenserende effekter på tryptophan og 5-hydroxytryptophan påvist i farmakologiske forsøg in vivo på dyr, og ligeledes in vitro. Samtidigt har forbindelserne praktisk taget ingen potenserende effekter på noradrenalin og adrenalin.
Forbindelserne med formlen I, hvori mindst en af substi-1 2 tuenterne R eller R er en cyano-gruppe eller R-CO, er hidtil ukendte, og især de cyanosubstituerede forbindelser udmærker sig ved at besidde de ønskede farmakologiske effekter i udpræget grad. For de øvrige forbindelser gælder det, at de ligeledes er hidtil ukendte, selvom de er omfattet af den brede formulering af krav 1 i ovennævnte danske patentbeskrivelse. Da de hverken har to methyl-grupper i 3-stillingen eller en monomethylamino-gruppe i sidekæden i 1-stillingen, har der overhovedet ikke foreligget nogen tilskyndelse til at fremstille og gennemprøve dem, og det har da også nu vist sig, at de ikke har nogen potenserende effekt på noradrenalin.
Fremgangsmåden ifølge opfindelsen er ejendommelig ved at a) en forbindelse med følgende formel: 4 143275 C2 ν^0Η
OH
— ch2 * CH2 CH2 · N (CH3) Λ v y hvori X og Y hver repræsenterer halogen eller en trifluor- methylgruppe, ringsluttes ved behandling med et dehydra- tiserende middel, og i det tilfælde, hvor x eller Y eller begge repræsenterer brom, den dannede forbindelse med formlen I, om ønsket, behandles med cuprocyanid i et inert organisk opløsningsmiddel for at opnå en forbindelse med 1 2 formlen I, hvori R eller R eller begge er en cyanogruppe, eller b) en forbindelse med den almene formel: c2 0
X
V
R2 1 2 hvori R og R er som defineret ovenfor, omsættes med et 3-dimethylaminopropylhalogenid i nærværelse af et kondensationsmiddel, eller c) en forbindelse med den almene formel: 5 143275 1 c2 o c <^CH 2 - CH 2 · CH 2 · N (CH 3) 2 Λ Y1 hvori X^" og Y^· hver repræsenterer halogen, en trifluor- methylgruppe eller en cyanogruppe, idet mindst en af X1 og Y repræsenterer en cyanogruppe, omsættes med et alkyl- magniumhalogenid med formlen RMghal, hvori R er som tidligere defineret, hvorpå det dannede Grignardkompleks hydrolyseres, hvorved dannes en forbindelse med formlen I, hvori mindst en 1 2 af R og R er R-CO-, hvorpå forbindelsen med formlen I isoleres som den frie amin eller et syreadditionssalt deraf med en farmaceutisk akcepterbar syre.
Ringslutningen ifølge metodevariant a) gennemføres ifølge opfindelsen hensigtsmæssigt,ved at der anvendes sædvanlige dehydratiseringsmidler, såsom koncentreret saltsyre, eventuelt blandet med iseddike, fosforsyrer, et hydrogenhalogenid, for eksempel hydrogenchlorid i et inert organisk opløsningsmiddel såsom chloroform, benzen eller toluen. Fortrinsvis anvendes svage til middelstærke sure dehydratiseringsmidler, idet anvendelsen af stærke dehydratiseringsmidler som koncentreret svovlsyre kan føre til uønskede derivater som beskrevet i britisk patentskrift nr. 939.856.
Udgangsforbindelserne med formlen II kan hensigtsmæssigt fremstilles ved at omsætte en forbindelse med følgende formel: ^2 0 hvori X er som defineret ovenfor med en Grignardforbindelse med følgende formel: Y —^ ^—Mghal 6 143275 hvori Y er som defineret ovenfor, hvorpå reaktionsblandingen underkastes en sur hydrolyse, og den dannede forbindelse med formlen: ?2 " Λ v
Y
isoleres og omsættes derpå med et N,N-dimethylaminopropyl-magniumhalogenid i en ether, såsom diethylether eller tetrahydrofuran, hvorpå den dannede forbindelse med formlen II isoleres på kendt måde efter hydrolyse.
Som kondensationsmidler ifølge metodevarianten b) anvendes ifølge opfindelsen hensigtsmæssigt et alkalimetalamid, f. eks.natriumamid eller kaliumamid, butyllithium eller phenyl-lithium, og reaktionen gennemføres hensigtsmæssigt i et inert organisk opløsningsmiddel såsom dimethylsulfoxyd, toluen eller benzen.
Som eksempler på farmaceutisk akcepterbare syrer, der ifølge opfindelsen kan finde anvendelse ved dannelsen af salte af forbindelserne med formlen I, kan eksempelvis nævnes hydrogen-chlorid, hydrogenbromid, fosforsyrer, svovlsyre, eddikesyre, propionsyre, vinsyre, maleinsyre, citronsyre, oxalsyre, benzosyre, methansulphonsyre og embonsyre.
Fremgangsmåden ifølge opfindelsen skal i det følgende illustreres ved en række eksempler.
7 143275
Eksempel 1.
En Grignardopløsning fremstillet af 220 g (1,15 mol)p-chloro-brombenzen og 29 g magniumspåner (1,2 mol) i 1500 ml tør ether dryppedes i løbet af en time til en suspension af 213 g 5-brom-phthalid (1 mol) i 1500 ml tør tetrahydrofuran. Reaktionstemperaturen blev holdt under 10°C. Efter endt tildrypning henstod reaktionsblandingen under omrøring i 3 timer ved stue ' temperatur. Blandingen hældtes derpå i 2 liter isvand og 100 ml mættet vandig ammoniumchloridopløsning tilføjedes. Etherfasen skiltes fra, og vand-tetrahydrofuranfasen ekstra-heredes med 500 ml ether. De kombinerede etherfaser vaskedes med vand, tørredes over vandfrit magniumsulfat, filtreredes og inddampedes, tilsidst i vakuum, hvorved vandtes 320 g 2-hydroxymethyl-4-brom-4'-chlor-benzofenoni form af en gul olie, som ikke rensedes yderligere men anvendtes direkte i det næste trin.
De 320 g olie opløstes i 200 ml tør tetrahydrofuran og dryppedes til et stort overskud af N,N-dimethylaminopropyl-magniumchlorid i tetrahydrofuran, idet reaktionsblandingen holdtes ved svag tilbagesvaling. Efter endt tildrypning holdtes blandingen under tilbagesvaling natten over. Reaktionsblandingen hældtes derpå i 5 liter isvand, og 200 ml mættet vandig ammoniumchloridopløsning tilføjedes. Blandingen ekstraheredes derpå med ialt 2500 ml ether.
Etherfasen ekstraheredes derpå med 20% vandig eddikesyre til sur reaktion, hvorpå eddikesyreopløsningen blev gjort alkalisk med 10N natriumhydroxydopløsning. Efter afkøling ekstraheredes den udskilte olie to gange med 500 ml ether.
De kombinerede etherekstrakter tørredes over vandfrit kalium-carbonat, behandledes med aktivt kul og inddampedes i vakuum. Remanensen- en 'gullig olie - bestod af 219 g urent (4-brom-2-(hydroxymethyl)phenyl)-(4-chlorphenyl)-(3-dimethylaminopropyl) methanol, som brugtes i næste trin uden yderligere rensning.
219 gr. olie fra det foregående trin opvarmedes i 3 timer på dampbad med 1800 ml 60% vandig fosforsyre under kraftig omrøring. Reaktionsblandingen neutraliseredes med ammoniakvand under vedvarende tilføjelse af knust is. Reaktions- 8 143275 blandingen ekstraheredes derpå med 1500 ml ether, etherfasen fraskiltes, tørredes over vandfrit kaliumcarbonat, behandledes med aktivt kul og inddampedes i vakuum. Remanensen destilleredes i vakuum, hvorved vandtes 105 g 1-(4'-chlorphenyl)-1-(3-dimethyl-aminopropyl)-5-bromphthalan som en olie, der kogte ved 188-190°C /o,l mm Hg.
Det tilsvarende oxalat fremstilledes på konventionel måde ved fældning fra ethanol og smeltede ved 178-180°C.
På tilsvarende måde fremstilledes følgende forbindelser med formlen I: 1-(4'-fluorphenyl)-1-(3-dimethylaminopropyl)-5-bromphthalan;
Kp. 174°C/o,l mm Hg; det tilsvarende oxalat smelter ved 148-150°C.
1-(4'-chlorphenyl)-1-(3-dimethylaminopropyl)-5-chlorphthalan; Oxalatet smelter ved 180-182°C, og hydrobromidet smelter ved 136-142°C.
1-(4'-bromphenyl)-l-(3-dimethylaminopropyl)-5-chlorphthalan;
Kp. 185°C / 0,08 mm Hg.
1-(4'-fluorphenyl)-1-(3-dimethylaminopropyl)-5-chlorphthalan;
Kp. 160-164°C / o,o5 mm Hg; Oxalatet smelter ved 152-155°C, og hydrochloridet smelter ved 168-171°C.
1-(4'-chlorphenyl)-1-(3-dimethylaminopropyl)-5-trifluormethyl-phthalan; Oxalatet smelter ved 184-186°C.
1-(4'-bromphenyl)-!-(3-dimethylaminopropyl)-5-trifluormethyl-phthalan; Kp. 162°C / o,2 mm Hg; Oxalatet smelter ved 190-193°C.
1-(4*-fluorphenyl)-1-(3-dimethylaminopropyl)-5-trifluormethyl-phthalan; Oxalatet smelter ved 141-147°C, og hydrochloridet smelter ved 159-161°C.
1-(4'-fluorphenyl)-1-(3-dimethylaminopropyl)-5-fluorphthalan;
Kp. 140°C / o,o2 mm Hg; hydrochloridet smelter ved 172-174°C.
1—(4'-chlorphenyl)-1-(3-dimethylaminopropyl)-5-fluorphthalan;
Kp. 161°C / o,o2 mm Hg; Oxalatet smelter ved 155-157°C.
9 143275
Eksempel 2. 105 g 1-(4'-chlorphenyl)-1-(3-dimethylamino- propyl)-5-bromphthalan og 28 g cuprocyanid i 75 ml dimethylformamid kogtes under tilbagesvaling i fire timer. Medens den endnu var varm, hældtes reaktionsblandingen i en opløsning af 55 ml ethylendiamin i 165 ml vand. Blandingen rystedes kraftigt,og den blåfarvede vandige fase decanteredes fra oliefasen. Den vandige fase ekstraheredes en gang med 200 ml benzen, og benzenfasen føjedes til oliefasen.
De samlede organiske faser vaskedes med 10% vandig natriumcyanidopløsning og vand, tørredes over vandfrit natriumsulfat, behandledes med aktivt kul og inddampedes. Den resulterende olie opløstes i ether og ekstraheredes med 20% vandig eddikesyre. Eddikesyreopløsningen blev gjort alkalisk med 10N vandig natriumhydroxydopløsning og ekstraheredes med ether. Etherfasen skiltes fra, tørredes over vandfrit kaliumcarbonat, behandledes med aktivt kul og inddampedes i vakuum.
Udbytte: 76 g 1-(4'-chlorphenyl)-1-(3-dimethylaminopropyl)-5- phthalancarbonitril. Hydrochloridet fremstilledes på konventionel måde og smeltede ved 148-150°C efter omkrystallisation af isopropylalkohol . På tilsvarende måde fremstilledes følgende forbindelser: 1-(4'-fluorphenyl)-1-(3-dimethylaminopropyl)-5-phthalan-carbonitril; Kp. 175°C / o,o3 mm Hg ; Oxalatet smelter ved 164-166°C, og hydrobromidet smelter ved 182-183°C.
1-(4' -cyanophenyl)-1-(3-dimethylaminopropyl)-5-phthalan-carbonitril; hydrochloridet smelter ved 167-169°C.
1-(4'-cyanophenyl)-1-(3-dimethylaminopropyl)-5-chlorphthalan;
Oxalatet smelter ved 187-191°C.
\ 1-(4'-cyanophenyl)-1-(3-dimethylaminopropyl)-5-trifluormethyl-phthalan; Oxalatet smelter ved 189-192°C.
Eksempel 3.
300 g 4-brom-41-fluor-2-(hydroxymethyl)benzofenon opløstes i 750 ml ether og dryppedes til en suspension af 25 g lithium-aluminiumhydrid i 900 ml ether med en sådan hastighed, at blandingen kogte under svag tilbagesvaling. Derpå kogtes ίο 143275 blandingen under tilbagesvaling i to timer, hvorpå den hydrolyseredes med vand. Etherfasen decanteredes fra de fældede metalsalte, som vaskedes to gange med ether.
De samlede etherfaser tørredes over vandfrit magniumsulfat og inddampedes i vakuum.
Udbytte: 305 g urent (4-brom-2-(hydroxymethyl)phenyl)-(4-fluorphenyl)methanol i form af en olie, som brugtes direkte i det næste trin.
De 305 g olie opvarmedes i tre timer på dampbad i 2400 ml 60% vandig fosforsyre under kraftig omrøring. Blandingen hældtes i to liter isvand og ekstraheredes med ether. Ether-fasen vaskedes til neutral reaktion med vand og tørredes over vandfrit magniumsulfat, behandledes med aktivt kul og inddampedes i vakuum. Remanensen (256 g) destilleredes i vakuum, hvorved 177 g 1-(4'-fluorphenyl)-5-bromphthalan, som kogte ved 170-175°C / 1 mm Hg, vandtes som en gul olie.
De 177 g olie og 62,5 g cuprocyanid i 200 ml dimethyl formamid kogtes under tilbagesvaling i fire timer. Reaktionsblandingen hældtes i en opløsning af 120 g natriumcyanid i 600 ml vand. Blandingen omrørtes i ti minutter og afkøledes. Krystallerne, som skilte ud, blev suget fra og filtratet ekstraheret en gang med 200 ml benzen. Krystallerne opløstes i 200 ml benzen, og de kombinerede benzenfaser ekstraheredes med 10% vandig natrium-cyanidopløsning og vand, tørredes over vandfrit magniumsulfat, behandledes med aktivt kul og inddampedes i vakuum. Ved afkøling udkrystalliserede 1-(4'-fluorphenyl)-5-phthalancarbo-nitril, petroleumether tilsattes, og krystallerne sugedes fra. Udbytte: 122 g, som smeltede ved 87-90°C.
Ved omkrystallisation af ether-petroleumether (1:1) vandtes 96 g, som smeltede ved 95-97°C.
21 g natriumhydrid (50% i mineralolie) opløstes i nitrogenatmosfære i 900 ml dimethylsulfoxyd ved 60-70°C. Til den dannede natriummethylsulfinylmethidopløsning tildryppedes under afkøling 96 g 1-(4'-fluorphenyl)-5-phthalancarbonitril opløst i 150 ml dimethylsulfoxyd. Reaktionstemperaturen holdtes omkring 25°C. Efter endt tildrypning omrørtes blandingen i 10 minutter ved stuetemperatur. Derpå tilføjedes hurtigt 53 g 3-dimethylaminopropylchlorid i 25 ml dimethylsulfoxyd, og reaktionsblandingen opvarmedes til 40°C og holdtes der 11 143275 i 50 minutter. Derpå hældtes blandingen i isvand og ekstra-heredes med ether. Etherfasen ekstraheredes med 20% vandig eddikesyre. Eddikesyreopløsningen blev gjort alkalisk med ION natriumhydroxydopløsning og ekstraheret med ether, som derpå vaskedes adskillige gange med vand. Etherfasen skiltes fra, tørredes over vandfrit kaliumcarbonat, behandledes med aktivt kul og inddampedes i vakuum. Remanensen var en olie (80 g), som destilleredes i vakuum, hvorved vandtes 56 g 1-(4'-fluorphenyl)-1-(3-dimethylaminopropyl)-5-phthalancarbo-nitril, som kogte ved 175-181°C / o,o3 mm Hg.
Det tilsvarende oxalat vandtes på konventionel måde af ethanol og smeltede ved 163-166°C. Hydrobromidet smelter ved 182-183°C.
På tilsvarende måde fremstilledes følgende forbindelse med formlen I: 1-(4'-chlorphenyl)-1-(3-dimethylaminopropyl)-5-propionyl-phthalanj Oxalatet smelter ved 134-139°C.
Eksempel 4. En opløsning af 1-(4-chlorphenyl)-1-(3-dimethylaminopropyl) -5-phthalancarbonitril (23 g, 0,068 mol) i 100 ml tør benzen føjedes til ethylmagniumbromid (fremstillet af 20 g ethylbromid og 4,8 g magniumspåner i 100 ml diethylether). Etheren destilleredes fra reaktionsblandingen indtil temperaturen nåede 70°C, hvorpå der kogtes under tilbagesvaling natten over. Blandingen hældtes derpå i en iskold vandig opløsning af ammoniumchlorid og ekstraheredes med ether. Den organiske fase ekstraheredes derpå med 4N saltsyre og ekstrakten opvarmedes i 2 timer på dampbad. Efter afkøling gjordes opløsningen alkalisk, ekstraheredes med ether, vaskedes med vand, tørredes og inddampedes, hvorved 18 g 1-(4-chlorphenyl)-1-(3-dimethylaminopropyl)-5-propionylphthalan vandtes som en gullig olie.
Oxalattet, som smeltede ved 134-139°C, vandtes på konventionel måde, efterfulgt af krystallisation fra methylisobutylketon.
Claims (2)
1. Analogifremgangsmåde til fremstilling af phthalaner med den almene formel:
0 I ^^CH2) 3 * N (CH3)
2 ΓΊ R2 1 2 hvori R og R hver repræsenterer halogen,en trifluor-methylgruppe, en cyanogruppe eller R-CO-, hvori R er en alkylgruppe med fra 1-4 carbonatomer inklusive, eller syreadditionssalte af disse forbindelser med farmaceutisk akcepterbare syrer, kendetegnet ved, at a) en forbindelse med følgende formel: X/Y I OH 11 CH2-N (CH3)2 A Y hvori X og Y hver repræsenterer halogen eller en trifluor- methylgruppe, ringsluttes ved behandling med et dehydra- tiserende middel, og i det tilfælde,hvor X eller Y eller begge repræsenterer brom, den dannede forbindelse med formlen I, om ønsket, behandles med cuprocyanid i et inert organisk opløsningsmiddel for at opnå en forbindelse med 1 2 formlen I, hvori R eller R eller begge er en cyanogruppe, 13 143275 eller b) en forbindelse med den almene formel: H2 0 m A R2 1 2 hvori R og R er som defineret ovenfor, omsættes med et 3-dimethylaminopropylhalogenid i nærværelse af et kondensationsmiddel, eller c) en forbindelse med den almene formel: 1 ^ j /° IV - CH„-CH0-CH_-N(CH0) _ AL· L· L· OL· V hvori X"^ og hver repræsenterer halogen, en trifluor- methylgruppe eller en cyanogruppe, idet mindst en af X* og Y1 repræsenterer en cyanogruppe, omsættes med et alkyl- magniumhalogenid med formlen RMghal, hvori R er som tidligere defineret, hvorpå det dannede Grignardkompleks hydrolyseres, hvorved dannes en forbindelse med formlen I, hvori mindst en 1 2 af R og R er R-CO-, hvorpå forbindelsen med formlen I isoleres som den frie amin eller et syreadditionssalt deraf med en farmaceutisk akcepterbar syre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB148676 | 1976-01-14 | ||
| GB1486/76A GB1526331A (en) | 1976-01-14 | 1976-01-14 | Phthalanes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK13177A DK13177A (da) | 1977-07-15 |
| DK143275B true DK143275B (da) | 1981-08-03 |
| DK143275C DK143275C (da) | 1982-01-18 |
Family
ID=9722860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13177A DK143275C (da) | 1976-01-14 | 1977-01-14 | Analogifremgangsmaade til fremstilling af 1-(3-dimethylaminopropyl)-phthalanderivater eller syreadditionssalte deraf |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4136193A (da) |
| JP (1) | JPS52105162A (da) |
| AT (1) | AT359488B (da) |
| AU (1) | AU509445B2 (da) |
| BE (1) | BE850401A (da) |
| CA (1) | CA1094087A (da) |
| CH (3) | CH626886A5 (da) |
| DE (1) | DE2657013C2 (da) |
| DK (1) | DK143275C (da) |
| ES (1) | ES454980A1 (da) |
| FI (1) | FI63754C (da) |
| FR (1) | FR2338271A1 (da) |
| GB (1) | GB1526331A (da) |
| IE (1) | IE44055B1 (da) |
| NL (2) | NL192451C (da) |
| NO (2) | NO147243C (da) |
| NZ (1) | NZ183001A (da) |
| SE (1) | SE429551B (da) |
| ZA (1) | ZA7757B (da) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602035A (en) * | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| DK0759299T3 (da) * | 1995-08-16 | 2000-08-07 | Lilly Co Eli | Potensering af serotoninrespons |
| ES2148120T3 (es) | 1997-07-08 | 2002-01-16 | Lundbeck & Co As H | Metodo para la preparacion de citalopram. |
| UA62985C2 (en) * | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
| EA002770B1 (ru) | 1997-11-11 | 2002-08-29 | Х.Лундбекк А/С | Способ получения циталопрама |
| PL199423B1 (pl) | 1998-10-20 | 2008-09-30 | Lundbeck & Co As H | Sposób wytwarzania citalopramu |
| KR20010081071A (ko) | 1998-12-08 | 2001-08-25 | 피터슨 존 메이달 | 벤조푸란 유도체, 그것들의 제조 및 사용 |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| IL143422A0 (en) | 1998-12-23 | 2002-04-21 | Lundbeck & Co As H | Method for the preparation of 5-cyanophthalide |
| AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
| DK1173431T4 (da) * | 1999-04-14 | 2010-01-04 | Lundbeck & Co As H | Fremgangsmåde til fremstilling af citalopram |
| ITMI991581A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991579A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991486A1 (it) * | 1999-07-06 | 2001-01-06 | Vis Farmaceutici S P A | Processo per la sintesi di citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| HRP20020344B1 (hr) | 1999-10-25 | 2010-10-31 | H. Lundbeck A/S | Način priprave citaloprama |
| GB2360281B (en) | 1999-10-25 | 2002-01-16 | Lundbeck & Co As H | Method for the preparation of citalopram |
| US6310222B1 (en) * | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
| AR026063A1 (es) | 1999-11-01 | 2002-12-26 | Lundbeck & Co As H | Metodo para la preparacion de 5-carboxiftalida. |
| HUP0203635A3 (en) | 1999-12-28 | 2005-02-28 | Lundbeck & Co As H | Method for the preparation of citalopram |
| PT1246813E (pt) * | 1999-12-30 | 2004-02-27 | Lundbeck & Co As H | Metodo para a preparacao de citalopram |
| CN1195749C (zh) * | 2000-01-14 | 2005-04-06 | H.隆德贝克有限公司 | 制备5-氰基2-苯并[c]呋喃酮的方法 |
| US6433196B1 (en) * | 2000-02-17 | 2002-08-13 | Sumika Fine Chemicals Co., Ltd. | Production method of citalopram, intermediate therefor and production method of the intermediate |
| NL1017415C1 (nl) * | 2000-02-24 | 2001-05-18 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| IES20010143A2 (en) * | 2000-02-24 | 2001-07-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
| NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
| IES20010206A2 (en) | 2000-03-13 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| CN1427835A (zh) * | 2000-03-13 | 2003-07-02 | H·隆德贝克有限公司 | 5-取代的1-(4-氟苯基)-1,3-二氢异苯并呋喃的分步烷基化 |
| KR20020080481A (ko) | 2000-03-13 | 2002-10-23 | 하. 룬트벡 아크티에 셀스카브 | 시탈로프람의 제조 방법 |
| TR200202155T2 (tr) | 2000-03-14 | 2002-12-23 | H. Lundbeck A/S | Sitalopramin preparasyon metodu |
| DE10190485T1 (de) * | 2000-03-16 | 2002-03-21 | Lundbeck & Co As H | Verfahren zur Herstellung von 5-Cyano-1-(4-fluorphenyl)-1,3-dihydroisobenzofuranen |
| JP2003530437A (ja) * | 2000-04-13 | 2003-10-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Aβ42低下物質 |
| US6977306B2 (en) | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| KR100821912B1 (ko) * | 2000-05-12 | 2008-04-16 | 하. 룬트벡 아크티에 셀스카브 | 시탈로프람의 제조 방법 |
| AR032455A1 (es) * | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
| CA2383963A1 (en) * | 2000-07-06 | 2002-01-17 | Eva Bolzonella | Method for the preparation of citalopram |
| AU8174001A (en) * | 2000-07-21 | 2002-02-05 | Lundbeck & Co As H | Novel compounds and their use as glycine transport inhibitors |
| IES20010693A2 (en) * | 2000-08-10 | 2002-07-10 | Lundbeck & Co As H | Pharmaceutical composition containing citalopram |
| CA2354877C (en) * | 2000-08-18 | 2006-05-02 | H. Lundbeck A/S | Method for the preparation of citalopram |
| US20030232881A1 (en) * | 2000-10-27 | 2003-12-18 | H. Lundbeck A/S | Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them |
| US20030109577A1 (en) * | 2000-10-27 | 2003-06-12 | Ken Liljegren | Pharmaceutical composition containing citalopram |
| IT1319686B1 (it) * | 2000-12-12 | 2003-10-23 | C D Farmasint S R L | Procedimento di preparazione di citalopram. |
| WO2001045483A2 (en) * | 2000-12-22 | 2001-06-28 | H. Lundbeck A/S | Method for the preparation of pure citalopram |
| JP2003519121A (ja) * | 2000-12-28 | 2003-06-17 | ハー・ルンドベック・アクチエゼルスカベット | 純粋なシタロプラムの製造方法 |
| DE10164725B4 (de) * | 2000-12-28 | 2004-08-26 | H. Lundbeck A/S | Verfahren zur Herstellung von gereinigtem Citalopram |
| DE10112828C1 (de) * | 2000-12-28 | 2002-11-21 | Lundbeck & Co As H | Verfahren zur Herstellung von Citalopram |
| AU2001100195B4 (en) * | 2001-01-05 | 2001-12-20 | H Lundbeck As | Pharmaceutical composition containing citalopram. |
| EP1355897A1 (en) | 2001-01-30 | 2003-10-29 | Orion Corporation Fermion | Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile |
| WO2002066453A1 (en) * | 2001-02-22 | 2002-08-29 | Natco Pharma Limited | Process for the preparation of citalopram |
| GB0105627D0 (en) * | 2001-03-07 | 2001-04-25 | Cipla Ltd | Preparation of phthalanes |
| JP2005500256A (ja) * | 2001-03-09 | 2005-01-06 | ランバクシー ラボラトリーズ リミテッド | シタロプラム製造方法 |
| WO2002087566A1 (en) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
| BG65271B1 (bg) * | 2001-06-18 | 2007-11-30 | H. Lundbeck A/S | Метод за получаване на циталопрам |
| AR034759A1 (es) * | 2001-07-13 | 2004-03-17 | Lundbeck & Co As H | Metodo para la preparacion de escitalopram |
| IN192057B (da) * | 2001-07-19 | 2004-02-14 | Ranbaxy Lab Ltd | |
| IL159326A0 (en) | 2001-07-31 | 2004-06-01 | Lundbeck & Co As H | Crystalline composition containing escitalopram |
| EP1288211A1 (en) * | 2001-08-28 | 2003-03-05 | Sekhsaria Chemicals Ltd. | Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
| US6967259B2 (en) * | 2001-09-24 | 2005-11-22 | Pharmachem Technologies Limited | Process for the preparation of Citalopram intermediate |
| MXPA04003358A (es) * | 2001-10-12 | 2004-07-08 | Serenix Pharmaceuticals Llc | Antagonistas de vasopresina v1a de ?-lactamilo. |
| IN192863B (da) * | 2001-11-13 | 2004-05-22 | Ranbaxy Lab Ltd | |
| IS7239A (is) * | 2001-12-14 | 2004-04-29 | H. Lundbeck A/S | Aðferð til framleiðslu á essítalóprami |
| US7148364B2 (en) * | 2002-01-07 | 2006-12-12 | Sun Pharmaceutical Industries | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile |
| GB0204607D0 (en) * | 2002-02-27 | 2002-04-10 | Matrix Lab Ltd | Process |
| GB2387844B (en) * | 2002-02-27 | 2005-05-11 | Matrix Lab Ltd | Separation of impurities from a crude mixture of citalopram |
| GB2385848A (en) * | 2002-02-27 | 2003-09-03 | Cipla Ltd | Citalopram salts |
| EP1346989A1 (en) * | 2002-03-21 | 2003-09-24 | Jubilant Organosys Limited | Improved process for the preparation of citalopram and its hydrobromide |
| TWI332938B (en) * | 2002-03-27 | 2010-11-11 | Bando Chemical Ind | Novel 1,3,5-tris(arylamino)benzenes |
| CA2381341A1 (en) * | 2002-04-09 | 2003-10-09 | Torcan Chemical Ltd. | Process and intermediates for preparing escitalopram |
| FI20021421A0 (fi) * | 2002-07-30 | 2002-07-30 | Orion Corp Fermion | Valmistusmenetelmä |
| AR040970A1 (es) | 2002-08-12 | 2005-04-27 | Lundbeck & Co As H | Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram |
| WO2004016602A1 (en) * | 2002-08-14 | 2004-02-26 | Natco Pharma Limited | Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts |
| GB2385051B (en) * | 2002-08-29 | 2003-12-24 | Max India Ltd | Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans |
| US6812355B2 (en) | 2002-10-22 | 2004-11-02 | Sekhsaria Chemicals Limited | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
| AU2003287919B2 (en) * | 2002-12-23 | 2009-11-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| AU2003242990A1 (en) * | 2003-01-17 | 2004-08-13 | Pulla Reddy Muddasani | Processes for the preparation of escitalopram and its precursor |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| ITMI20030479A1 (it) * | 2003-03-13 | 2004-09-14 | Adorkem Technology S P A | Procedimento per la preparazione di un ciano-isobenzofurano. |
| US7019153B2 (en) * | 2003-06-10 | 2006-03-28 | Sun Pharmaceutical Industries Limited | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid |
| KR20060040676A (ko) * | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
| GB0317475D0 (en) * | 2003-07-25 | 2003-08-27 | Meditab Specialities Pvt Ltd | Product |
| ITFI20030202A1 (it) * | 2003-07-28 | 2005-01-29 | Synteco Spa | Processo per la preparazione di derivati del |
| ES2319539T3 (es) * | 2003-09-17 | 2009-05-08 | Janssen Pharmaceutica Nv | Compuestos heterociclicos condensados como moduladores del receptor de serotonina. |
| AU2003278409A1 (en) * | 2003-10-28 | 2005-05-19 | Krishnaji Upadhye Bhargav | Improved process for the manufacture of citalopram hydrobromide |
| PT1506963E (pt) * | 2003-10-28 | 2005-08-31 | Adorkem Technology Spa | Processo para a preparacao de citalopram |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| EP1708790B1 (en) * | 2003-12-02 | 2010-04-21 | PharmaNeuroBoost N.V. | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| CN100569765C (zh) * | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | 西酞普兰中间体晶体碱 |
| TWI339651B (en) * | 2004-02-12 | 2011-04-01 | Lundbeck & Co As H | Method for the separation of intermediates which may be used for the preparation of escitalopram |
| EP1723133A1 (en) * | 2004-02-16 | 2006-11-22 | Jubilant Organosys Limited | One pot synthesis of citalopram from 5-cyanophthalide |
| US20050196453A1 (en) * | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
| ITMI20040717A1 (it) * | 2004-04-09 | 2004-07-09 | Adorkem Technology Spa | Procedimento chemo-enzimatico per la preparazione dell'escitalopram |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | COMBINATIONS OF LITHIUM AND USES THEREOF |
| AU2005241023A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| ES2285972T1 (es) | 2004-08-23 | 2007-12-01 | Sun Pharmaceutical Industries Limited | Procedimiento de fabricacion de citalopram y enantiomeros. |
| US7989645B2 (en) * | 2004-08-23 | 2011-08-02 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
| WO2006102283A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| WO2006103550A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Processes for the preparation of citalopram and its intermediate 5-aminophthalide |
| AU2006239942A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| US7368477B2 (en) | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
| EP1879875A1 (en) * | 2005-04-22 | 2008-01-23 | Wyeth | Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| TW200718692A (en) | 2005-04-22 | 2007-05-16 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| TWI347942B (en) | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| EP2317316A3 (en) | 2005-07-08 | 2011-06-15 | Braincells, Inc. | Methods for identifying agent and conditions that modulate neurogenesis |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| EP1910346B1 (en) | 2005-07-19 | 2019-02-27 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist |
| CA2615063A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US7598255B2 (en) * | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| JP2009515840A (ja) * | 2005-11-14 | 2009-04-16 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムの製造方法 |
| GB0601286D0 (en) | 2006-01-23 | 2006-03-01 | Sandoz Ag | Asymmetric synthesis |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| EP1998773A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | New therapeutic combinations for the treatment of depression |
| JP2009536667A (ja) * | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5ht受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| JP4927497B2 (ja) * | 2006-10-25 | 2012-05-09 | 株式会社シスコ | 無湿乾燥用ホッパー装置 |
| CN100457747C (zh) * | 2006-11-21 | 2009-02-04 | 浙江大学 | 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺 |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| AU2008204800A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| US7566793B2 (en) * | 2007-04-23 | 2009-07-28 | Synthon Bv | Process for resolving citalopram |
| JP2010527345A (ja) * | 2007-05-18 | 2010-08-12 | シプラ・リミテッド | エスシタロプラムの調製方法 |
| US20080312318A1 (en) * | 2007-06-14 | 2008-12-18 | Protia, Llc | Deuterium-enriched escitalopram |
| EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
| US8022232B2 (en) * | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
| KR101103118B1 (ko) * | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| EP2116231A1 (en) | 2008-05-07 | 2009-11-11 | Hexal Ag | Granulate comprising escitalopram oxalate |
| US20100087664A1 (en) * | 2008-10-07 | 2010-04-08 | Ravindra Vedantham | Preparation of citalopram and salts thereof |
| GR20080100696A (el) | 2008-10-23 | 2010-05-13 | Genepharm �.�. | Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| PL3351104T3 (pl) | 2010-07-01 | 2021-06-14 | Azevan Pharmaceuticals, Inc. | Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych |
| WO2013100870A1 (en) | 2011-12-02 | 2013-07-04 | Mahmut Bilgic | New antipsychotic compositions |
| WO2013081567A1 (en) | 2011-12-02 | 2013-06-06 | Mahmut Bilgic | Effervescent antipsychotic formulations |
| WO2013110313A1 (en) * | 2012-01-23 | 2013-08-01 | H. Lundbeck A/S | Selective allosteric modulators of the serotonin transporter |
| SG10202001065SA (en) | 2014-03-28 | 2020-04-29 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases |
| MD3426251T2 (ro) | 2016-03-10 | 2022-09-30 | Janssen Pharmaceutica Nv | Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2 |
| MX2020002762A (es) | 2017-09-15 | 2020-09-17 | Azevan Pharmaceuticals Inc | Composiciones y métodos para tratar una lesión cerebral. |
| BR112022000992A2 (pt) | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (da) * | 1965-03-18 |
-
1976
- 1976-01-14 GB GB1486/76A patent/GB1526331A/en not_active Expired
- 1976-12-16 DE DE2657013A patent/DE2657013C2/de not_active Expired
- 1976-12-17 SE SE7614201A patent/SE429551B/xx not_active IP Right Cessation
- 1976-12-21 AT AT947276A patent/AT359488B/de active Protection Beyond IP Right Term
-
1977
- 1977-01-04 IE IE5/77A patent/IE44055B1/en not_active IP Right Cessation
- 1977-01-05 ZA ZA770057A patent/ZA7757B/xx unknown
- 1977-01-05 AU AU21073/77A patent/AU509445B2/en not_active Expired
- 1977-01-06 NZ NZ183001A patent/NZ183001A/en unknown
- 1977-01-07 US US05/757,619 patent/US4136193A/en not_active Expired - Lifetime
- 1977-01-11 FI FI770073A patent/FI63754C/fi not_active IP Right Cessation
- 1977-01-12 ES ES454980A patent/ES454980A1/es not_active Expired
- 1977-01-12 NL NL7700244A patent/NL192451C/nl not_active IP Right Cessation
- 1977-01-13 CA CA000269610A patent/CA1094087A/en not_active Expired
- 1977-01-13 NO NO770109A patent/NO147243C/no unknown
- 1977-01-13 JP JP199777A patent/JPS52105162A/ja active Granted
- 1977-01-13 CH CH42377A patent/CH626886A5/de not_active IP Right Cessation
- 1977-01-14 FR FR7701079A patent/FR2338271A1/fr active Granted
- 1977-01-14 DK DK13177A patent/DK143275C/da active
- 1977-01-14 BE BE174098A patent/BE850401A/xx not_active IP Right Cessation
-
1981
- 1981-06-01 CH CH357581A patent/CH632259A5/de not_active IP Right Cessation
- 1981-06-01 CH CH357481A patent/CH632258A5/de not_active IP Right Cessation
-
1996
- 1996-01-05 NO NO1996001C patent/NO1996001I1/no unknown
-
1997
- 1997-08-04 NL NL970031C patent/NL970031I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK143275B (da) | Analogifremgangsmaade til fremstilling af 1-(3-dimethylaminopropyl)-phthalanderivater eller syreadditionssalte deraf | |
| CA2354877C (en) | Method for the preparation of citalopram | |
| BR112020012457A2 (pt) | preparação de nicotina racêmica por reação de nicotinato de etila com n-vinilpirrolidona na presença de uma base de alcoolato e subsequentes etapas de processo | |
| PL131190B1 (en) | Process for preparing novel derivatives of dihydropyridine | |
| JP2637737B2 (ja) | 新規な薬剤 | |
| BR112020012458A2 (pt) | preparação de nicotina racêmica por reação de nicotinato de etila com n-vinilpirrolidona na presença de uma base de alcoolato e subsequentes etapas de processo | |
| MXPA02008230A (es) | Metodo para la preparacion de citalopram. | |
| CA1306261C (fr) | 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments | |
| NO162176B (no) | Middel for bekjempelse av plantesykdommer og anvendelse derav. | |
| AU625664B2 (en) | 3,4-Dehydropiperidine derivatives having psychotropic activity | |
| DK166584B1 (da) | Substituerede 4-benzyl-1h-imidazoler, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende dem | |
| IE42978B1 (en) | Triaryl alkyl azabicyclo compounds | |
| EA005491B1 (ru) | Способ получения циталопрама | |
| FR2480284A1 (fr) | Amines antihypertensives, leur procede de preparation et compositions antihypertensives en contenant. | |
| NO772604L (no) | Fremgangsm}te for fremstilling av derivater av fenoksyhydroksypropylamin | |
| US4616017A (en) | Aminohydroxypropoxy substituted aryl compounds | |
| JPS62281860A (ja) | アルキレンアミノアルキレン ヘテロ原子基を有するジヒドロ−3,5−ジカルボキシレ−ト | |
| JPS6341460A (ja) | 新規なジヒドロピリジン誘導体 | |
| JPH0337549B2 (da) | ||
| US4101660A (en) | 2-Aminomethyl-5-phenyloxazoles and the pharmaceutically acceptable acid addition salts thereof | |
| US2570286A (en) | Tertiary-amino-2-aryl-2-(4-quinolyl) alkane-nitriles and their preparation | |
| JPS58177992A (ja) | イソキサゾ−ル−〔5,4−b〕−ピリジン類 | |
| DK156391B (da) | Analogifremgangsmaade til fremstilling af 3-aminopyrrolderivater | |
| US4123541A (en) | 2-Aminomethyl-5-phenyloxazoles and the pharmaceutically acceptable salts thereof | |
| DK144299B (da) | Analogifremgangsmaade til fremstilling af 1-fenyl2-amino-1,3-propandiol-n-alkyl-derivater eller fysiologisk acceptable salte deraf |